New drug combo targets Hard-to-Treat head and neck cancer
NCT ID NCT07090317
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests two drugs, Iparomlimab and Tuvonralimab, in 30 adults with recurrent or metastatic head and neck cancer that has not responded to at least two prior treatments. Participants receive the drugs by IV every 21 days. The main goal is to see if the combination can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Iparomlimab and Tuvonralimab (drugs given by IV infusion every 21 days)
- What this could lead to
- If successful, this could offer a new treatment option for patients with advanced head and neck cancer who have run out of standard therapies.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The drugs may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200011, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug cocktail aims to tackle recurrent head and neck cancer
- New drug combo targets Hard-to-Treat head and neck cancers
- Promising drug cocktail targets Hard-to-Treat head and neck cancer
- New hope for head and neck cancer: drug combo shows promise after standard treatment fails
- Promising combo therapy for head and neck cancer hits early snag
- Gut health boost may tame immunotherapy side effects in head and neck cancer